Pulmonology · Medical Literature
The effects of asymmetrical versus symmetrical high-flow nasal cannula on respiratory muscle activity in acute hypoxaemic respiratory failure and chronic obstructive pulmonary disease: A randomised crossover study.
Abstract
High-flow nasal cannula (HFNC) is standard therapy for acute hypoxaemic respiratory failure and is increasingly used in hypercapnic COPD. Comparative data between the asymmetrical and conventional HFNC interfaces regarding respiratory muscle work of breathing is limited. This study aimed to compare the effects of both HFNC interfaces on diaphragm and parasternal intercostal thickening fraction (TFdi and TFpi), and other physiological variables. This randomised crossover study enrolled two cohorts: 20 subjects with acute hypoxaemic respiratory failure and 18 subjects with COPD exacerbation. At baseline, subjects received low-flow oxygen cannula for 15 min then underwent randomised 15 min-sequences of asymmetrical and symmetrical HFNC at flow rates of 40 and 60 L/min, with 5-min washouts. Primary outcome was change in TFdi. Secondary outcomes were TFpi, power of breathing (TFdi × respiratory rate), and other physiological variables. TFdi, TFpi, power of breathing, and PtcCO2 were significantly lower than baseline with both HFNC interfaces at 40 and 60 L/min in both groups (p < 0.05). In acute hypoxaemic respiratory failure, compared to symmetrical HFNC, asymmetrical HFNC was associated with greater reduction in respiratory rate (p < 0.001) and power of breathing (p < 0.001) at both flow rates. In COPD exacerbation, compared to symmetrical HFNC, asymmetrical HFNC reduced respiratory rate at both flow rates (p < 0.001). Both HFNC interfaces reduced respiratory muscle workload compared to baseline in both cohorts. In acute hypoxaemic respiratory failure, asymmetrical HFNC reduced respiratory rate and power of breathing more than symmetrical HFNC. In COPD exacerbation, the asymmetrical HFNC lowered respiratory rate more than the symmetrical HFNC. This study was registered with ClinicalTrial.gov (registration number: NCT06204276) before enrolment and approved by the Siriraj Institutional Review Board (certificate of approval - Si873/2023).
Clinical relevance
In patients with acute hypoxaemic respiratory failure or COPD exacerbation, does an asymmetrical HFNC interface produce greater reductions in diaphragm thickening fraction (a marker of respiratory muscle effort) compared to a conventional symmetrical HFNC interface at flow rates of 40 and 60 L/min? __SNAPSHOT__ {"studyDesign":"Randomised crossover physiological study with two parallel cohorts","setting":"Not reported (inpatient hospital setting inferred from clinical context; country not specified in abstract)","sampleSize":"n=38 total (Cohort 1: n=20 acute hypoxaemic respiratory failure; Cohort 2: n=18 COPD exacerbation)","population":"Two cohorts: (1) adults with acute hypoxaemic respiratory failure; (2) adults with COPD exacerbation. Detailed inclusion/exclusion criteria beyond respiratory acidosis (pH 45 mmHg), haemodynamic instability, altered mental status, active pneumothorax, and pregnancy not fully reported in the abstract.","intervention":"Asymmetrical HFNC interface (Optiflow Duet system, Fisher & Paykel Healthcare) at 40 L/min and 60 L/min, each for 15-minute sequences","comparator":"Symmetrical (conventional) HFNC interface at 40 L/min and 60 L/min, each for 15-minute sequences; low-flow oxygen cannula as baseline for 15 minutes","primaryOutcome":"Change in diaphragm thickening fraction (TFdi) from baseline, assessed by ultrasound","followUp":"Acute crossover protocol only; each condition lasted 15 minutes with 5-minute washout periods. No longitudinal follow-up reported.","fundingSource":"Not reported in abstract"}
Key findings
Both asymmetrical and symmetrical HFNC interfaces, at both 40 and 60 L/min, produced statistically significant reductions from low-flow oxygen baseline in diaphragm thickening fraction (TFdi), parasternal intercostal thickening fraction (TFpi), power of breathing (TFdi × respiratory rate), and transcutaneous PCO2 (PtcCO2) in both patient cohorts (p<0.05 for all comparisons vs. baseline). The abstract, as provided, is truncated and does not report the primary between-interface comparison (asymmetrical vs. symmetrical HFNC) for TFdi, TFpi, power of breathing, or PtcCO2 in either cohort. Accordingly, absolute or relative effect sizes, confidence intervals, and p-values for the head-to-head interface comparison are not reported in the available abstract text. NNT/NNH cannot be calculated from a physiological crossover study using continuous surrogate endpoints. No adverse events are reported in the abstract. The primary conclusion regarding whether the asymmetrical interface confers superior respiratory muscle unloading compared to the symmetrical interface remains unavailable from the abstract alone.
Practice implications
The study confirms that both HFNC interface types reduce markers of respiratory muscle effort and CO2 burden relative to low-flow oxygen in both acute hypoxaemic respiratory failure and COPD exacerbation — a physiologically expected finding consistent with prior literature. However, because the abstract is truncated, the study's central comparative finding — whether the asymmetrical interface is superior, inferior, or equivalent to the symmetrical interface for respiratory muscle unloading — cannot be determined from the available text. The study employed short 15-minute exposure periods per condition, which may not reflect sustained physiological adaptation or real-world clinical outcomes. Surrogate endpoints (TFdi, TFpi) are validated physiological markers but are not established as surrogates for clinically meaningful outcomes such as intubation avoidance, ICU length of stay, or mortality. Patients with severe respiratory acidosis, haemodynamic instability, and altered mental status were excluded, limiting generalisability to the most critically ill. The COPD cohort was studied during exacerbation, where NIV remains the evidence-based first-line intervention, and findings should not be interpreted as support for substituting HFNC for NIV in this population. IMPORTANT: This summary is based exclusively on a truncated abstract; access to the full text is required for complete clinical interpretation, including all comparative results and statistical analyses. Only abstract-available data have been used; no values have been extrapolated or invented. __LIMITATIONS__ Abstract is truncated — the primary between-interface comparative results (asymmetrical vs. symmetrical HFNC) are absent from the available text, precluding complete evidence appraisal.,Small sample sizes in both cohorts (n=20 and n=18), with high risk of insufficient power for subgroup comparisons.,Short 15-minute exposure per condition may not capture sustained physiological effects or treatment tolerance.,Crossover design with only 5-minute washout periods raises concern for inadequate washout, particularly for transcutaneous CO2 normalisation.,Surrogate physiological endpoints (TFdi, TFpi, PtcCO2) — no clinical outcomes (intubation rate, mortality, ICU length of stay) reported.,Setting, funding source, and allocation concealment details not reported in abstract.,Exclusion of patients with severe respiratory acidosis limits generalisability to the most critically ill patients who might most benefit from HFNC optimisation.,In the COPD exacerbation cohort, NIV is guideline-recommended first-line therapy; the role of HFNC as a comparator to or replacement for NIV is not addressed.,Statistical significance at p<0.05 vs. baseline does not establish clinical importance of interface differences, if any exist.,Whether the asymmetrical interface offers meaningful advantages over the symmetrical interface cannot be assessed from the truncated abstract. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ Both asymmetrical and symmetrical HFNC interfaces significantly reduced markers of respiratory muscle effort (TFdi, TFpi, power of breathing) and PtcCO2 compared to low-flow oxygen in acute hypoxaemic respiratory failure and COPD exacerbation — consistent with established HFNC physiology. The central comparative question of whether the asymmetrical interface provides superior respiratory muscle unloading over the symmetrical interface cannot be answered from the truncated abstract, and full-text review is mandatory before any interface selection guidance can be derived. This study should be considered preliminary physiological data only; interface choice in clinical practice should not be altered based on these results until the complete findings are evaluated.